Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that Remi Barbier, its President & CEO, will discuss clinical and corporate updates for Q1 2022 in a fireside chat and presentation on Tuesday, April 5, 2022, at 9am Eastern time.
This event, open to the public, will be conducted exclusively via webcast.
Stakeholders are encouraged to submit questions or comments for management’s consideration. Please email in advance of the event your questions and full name to: This email address is being protected from spambots. You need JavaScript enabled to view it.
Management may not be able to address all comments or questions due to SEC Regulation Fair Disclosure (FD), limits around legal disclosures, time constraints or other limitations.
Detailed instructions on how to attend the webcast will be made available prior to the event. A webcast of Cassava Sciences’ fireside chat will be available for replay following the event on www.CassavaSciences.com in the ‘Investors’ section.
About Cassava Sciences, Inc.
Cassava Sciences’ mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer’s disease. We are currently testing simufilam, our lead drug candidate for the proposed treatment of Alzheimer’s disease, in Phase 3 clinical studies under Special Protocol Assessments from the FDA. Simufilam is also being tested in an open-label study and a randomized, double-blind, placebo-controlled Cognition Maintenance Study in patients with Alzheimer’s disease.
For more information, please visit: https://www.CassavaSciences.com
For More Information Contact:
Eric Schoen, Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
(512) 501-2450
| Last Trade: | US$2.35 |
| Daily Change: | 0.06 2.62 |
| Daily Volume: | 3,158,260 |
| Market Cap: | US$113.060M |
November 25, 2024 November 07, 2024 September 24, 2024 September 09, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
